Clinical Trials
Our Team

Clinical Trials

If you are interested in any of the trials or think that you meet the criteria to participate, please call the Presence Cancer Care at 815.730.3098.


Connect AZA-MDS-006 : AML and MDS Registry
The Connect MDS and AML Disease Registry is a prospective, longitudinal, multi-center observational cohort study of patients with newly diagnosed MDS or AML Study


NCT# 02513394 AFT-05, NSABP B-57-I : Adjuvant Breast
Alliance AFT-05: PALLAS: PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

GO29831 : Her2-Positive/Negative Breast Cancer
A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of Atezolizumab (Anti-Pd-L1 Antibody) In Combination W/ Trastuzumab Emtansine Or W/ Trastuzumab And Pertuzumab (W/ And W/O Docetaxel) In Patients W/ Her2-Positive Breast Cancer And Atezolizumab W/ Doxorubicin And Cyclophosphamide In Her2-Negative Breast Cancer

E2112 NCT 02115282 : Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer

A5481082 : Observational: Hormone Receptor Positive Advanced Breast Cancer
Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study

NRG- BR003 NCT 02488967 : Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjudavant Therapy Comparing Doxorubib Plus Cyclophosphanide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer


PM1183-C-003-14 : 2nd line limited or extensive stage SCLC
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)

NCT 02201992 E4512 : ALK Fusion NSCLC
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

NCT 02193282 CTSU/A081105 : EGFR Mutant NSCLC
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

NCT 02193282 CTSU/A151216 : NSCLC
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST)


E7080-G00-307 : Advanced Renal Cell
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma


MK3475-361 : First-Line Advanced or Metastatic Urothelial Cancer
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma


MIT-201701 : CANscript Observational Various Solid Cancers
Various types of advanced solid cancer (e.g. squamous cell carcinoma of the head and neck (HNSCC), triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), epithelial ovarian cancer (EOC), and colorectal cancer (CRC)

Our Team

Dr. Kulumani M. Sivarajan, MD

Medical Director of Clinical Research:
Dr. Jason Suh, MD

Manager of Clinical Research:
Karen Sceniak, CCRC

Clinical Research Coordinators:
Maureen Clennon

Dipti Tambe

Data Manager:
Jennifer Crocker

Regulatory Affairs Manager:
Joan Pufahl